Literature DB >> 18457419

Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex.

Nicholas R Silvaggi1, David Wilson, Saul Tzipori, Karen N Allen.   

Abstract

The Clostridium botulinum neurotoxin serotype A light chain (BoNT/A-LC) is a Zn(II)-dependent metalloprotease that blocks the release of acetylcholine at the neuromuscular junction by cleaving SNAP-25, one of the SNARE proteins required for exocytosis. Because of the potential for use of the toxin in bioterrorism and the increasingly widespread application of the toxin in the medical field, there is significant interest in the development of small-molecule inhibitors of the metalloprotease. Efforts to design such inhibitors have not benefited from knowledge of how peptides bind to the active site since the enzyme-peptide structures available previously either were not occupied in the vicinity of the catalytic Zn(II) ion or did not represent the product of SNAP-25 substrate cleavage. Herein we report the 1.4 A-resolution X-ray crystal structure of a complex between the BoNT/A-LC and the inhibitory peptide N-Ac-CRATKML, the first structure of the light chain with an inhibitory peptide bound at the catalytic Zn(II) ion. The peptide is bound with the Cys S gamma atom coordinating the metal ion. Surprisingly, the cysteine sulfur is oxidized to the sulfenic acid form. Given the unstable nature of this species in solution, is it likely that oxidation occurs on the enzyme. In addition to the peptide-bound structure, we report two structures of the unliganded light chain with and without the Zn(II) cofactor bound at 1.25 and 1.20 A resolution, respectively. The two structures are nearly identical, confirming that the Zn(II) ion plays a purely catalytic role. Additionally, the structure of the Zn(II)-bound uncomplexed enzyme allows identification of the catalytic water molecule and a second water molecule that occupies the same position as the peptidic oxygen in the tetrahedral intermediate. This observation suggests that the enzyme active site is prearranged to stabilize the tetrahedral intermediate of the protease reaction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18457419     DOI: 10.1021/bi8001067

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  28 in total

1.  SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E.

Authors:  Rakhi Agarwal; Subramanyam Swaminathan
Journal:  J Biol Chem       Date:  2008-07-25       Impact factor: 5.157

Review 2.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.

Authors:  Sergio Pantano; Cesare Montecucco
Journal:  Cell Mol Life Sci       Date:  2013-06-11       Impact factor: 9.261

3.  Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.

Authors:  Lucy Lin; Margaret E Olson; Takashi Sugane; Lewis D Turner; Margarita A Tararina; Alexander L Nielsen; Elbek K Kurbanov; Sabine Pellett; Eric A Johnson; Seth M Cohen; Karen N Allen; Kim D Janda
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

4.  Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A.

Authors:  Lucy Lin; Lewis D Turner; Peter Šilhár; Sabine Pellett; Eric A Johnson; Kim D Janda
Journal:  RSC Med Chem       Date:  2020-11-12

5.  Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.

Authors:  Jorge E Zuniga; Jared T Hammill; Omri Drory; Jonathan E Nuss; James C Burnett; Rick Gussio; Peter Wipf; Sina Bavari; Axel T Brunger
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

6.  Small molecules showing significant protection of mice against botulinum neurotoxin serotype A.

Authors:  Yuan-Ping Pang; Jon Davis; Shaohua Wang; Jewn Giew Park; Madhusoodana P Nambiar; James J Schmidt; Charles B Millard
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

7.  Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency.

Authors:  Steven C Cardinale; Michelle M Butler; Gordon Ruthel; Jonathan E Nuss; Laura M Wanner; Bing Li; Ramdas Pai; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Botulinum J       Date:  2011

8.  Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies.

Authors:  Peter Šilhár; Nicholas R Silvaggi; Sabine Pellett; Kateřina Čapková; Eric A Johnson; Karen N Allen; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2012-12-20       Impact factor: 3.641

9.  The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.

Authors:  Rahman M Mizanur; Verna Frasca; Subramanyam Swaminathan; Sina Bavari; Robert Webb; Leonard A Smith; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

10.  Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design.

Authors:  Yuan-Ping Pang; Anuradha Vummenthala; Rajesh K Mishra; Jewn Giew Park; Shaohua Wang; Jon Davis; Charles B Millard; James J Schmidt
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.